Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

類似資料

• Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
  著者:: Minhas, R, 等
  出版事項: (2009)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  著者:: Neil, A, 等
  出版事項: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
  著者:: Neil, H, 等
  出版事項: (2003)
• Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
  著者:: Neil, H, 等
  出版事項: (2004)
• CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
  著者:: M. Doortje Reijman, 等
  出版事項: (2024-03-01)